Tactile Systems Technology, Inc., a medical technology company specializing in therapies for chronic disorders, reported its financial results for the second quarter of 2025. The company posted a total revenue increase of 7.8% year-over-year, reaching $78.9 million. The gross margin improved to 75% from 74% in the same quarter of 2024. Net income for the second quarter was $3.2 million, or $0.14 per diluted share, a decrease from $4.3 million, or $0.18 per diluted share, in the second quarter of 2024. Adjusted EBITDA was $7.7 million compared to $9.1 million in the prior-year period. Operating income decreased to $4.1 million from $5.8 million in the second quarter of 2024. Other income, primarily from interest, rose to $0.4 million from $0.2 million in the same quarter of the previous year. The income tax expense was reduced to $1.3 million, down from $1.8 million in Q2 2024. The company also highlighted the completion of its share repurchase program, having repurchased $16.5 million of stock. Additionally, Tactile Systems announced new data that demonstrates significant benefits of its Flexitouch Plus product for patients with head and neck cancer-related lymphedema. CEO Sheri Dodd expressed confidence that the company's momentum would continue into the second half of the year, supported by a favorable payer policy environment and healthy channel call points.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.